David A Buchen Net Worth

The estimated Net Worth of David A Buchen is at least 239 千$ dollars as of 3 January 2020. David Buchen owns over 27,614 units of Amneal Pharmaceuticals Inc stock worth over 239,213$ and over the last 12 years David sold AMRX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Buchen AMRX stock SEC Form 4 insiders trading

David has made over 4 trades of the Amneal Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently David exercised 27,614 units of AMRX stock worth 230,853$ on 3 January 2020.

The largest trade David's ever made was exercising 27,614 units of Amneal Pharmaceuticals Inc stock on 3 January 2020 worth over 230,853$. On average, David trades about 6,261 units every 249 days since 2013. As of 3 January 2020 David still owns at least 28,614 units of Amneal Pharmaceuticals Inc stock.

You can see the complete history of David Buchen stock trades at the bottom of the page.

What's David Buchen's mailing address?

David's mailing address filed with the SEC is 400 Interpace Pkwy, Parsippany, NJ 07054, USA.

Insiders trading at Amneal Pharmaceuticals Inc

Over the last 7 years, insiders at Amneal Pharmaceuticals Inc have traded over 867,197,480$ worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth 12,997,905$ . The most active insiders traders include Gp A, Llcbonderman Davidcou...、Holdings, Llc Aphc、International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of 3,857,739$. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth 491,654$.

What does Amneal Pharmaceuticals Inc do?

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.

Complete history of David Buchen stock trades at Enact Inc、Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Inc executives and stock owners

Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Andrew Boyer,
  Executive Vice President - Commercial Operations
• Chintu Patel R.Ph, R.Ph.,
  Co-Founder, Co-CEO & Director
• Nikita Shah,
  Chief Human Resource Officer, Senior Vice President
• Andrew S. Boyer,
  Exec. VP & Chief Commercial Officer of Generics
• Anastasios G. Konidaris,
  Exec. VP & CFO
• Joseph Todisco MBA,
  Exec. VP & Chief Commercial Officer of Specialty
• Nikita Shah,
  Exec. VP and Chief HR Officer & Strategic Planning Officer
• J. Kevin Buchi,
  Independent Director
• Ted Nark,
  Independent Director
• Emily Alva,
  Independent Director
• Gautam Patel,
  Director
• Chintu Patel,
  Co-Chief Executive Officer, Co-Founder, Director
• Chirag Patel,
  President, Co-Chief Executive Officer, Director
• Paul Meister,
  Independent Chairman of the Board
• Shlomo Yanai,
  Independent Director
• John Kiely,
  Independent Director
• Jeffrey George,
  Independent Director
• Chintu Patel R.Ph., R.Ph,
  Co-Founder, Co-CEO & Director
• Chirag K. Patel,
  Co-Founder, Co-CEO, Pres & Director
• Joseph Todisco,
  Senior Vice President - Specialty Commercial
• Apurva Saraf,
  Senior Vice President - Corporate Development
• Joseph Greer,
  Senior Vice President - Global Quality Management
• Stephen Manzano,
  Senior Vice President, General Counsel & Corporate Secretary
• Sanjay Jain,
  President - India
• Anastasios Konidaris,
  Chief Financial Officer, Senior Vice President
• Jason B. Daly Esq.,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Dr. Nikunj Patel,
  Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd
• Sanjiv Patel,
  Sr. VP of Operations
• Stephen J. Manzano,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Anthony DiMeo,
  Sr. Director of Investor Relations
• Sheldon Hirt,
  SVP, GC & Corp. Sec.
• Jean Selden Greene,
  Director
• Holdings, Llc Aphc,
  10% owner
• Robert L Burr,
  Director
• Bryan M. Reasons,
  CFO
• Robert A Stewart,
  President and CEO
• Dharmendra Rama,
  Director
• Janet S. Vergis,
  Director
• Peter R Terreri,
  Director
• Paul Bisaro,
  Executive Chairman
• David A Buchen,
  SVP, Chief Legal Officer
• Todd P. Branning,
  SVP and CFO
• Pradeep Bhadauria,
  SVP, Chief Scientific Officer
• International Ltd Fosun,
  10% owner
• Gustavo Pesquin,
  See Remarks
• Gp A, Llcbonderman Davidcou...,
  
• Tasos Konidaris,
  Executive Vice President & CFO
• Jason B. Daly,
  SVP, Chief Legal Officer
• Deborah M. Autor,
  Director
• Dipan Patel,
  
• Tushar Bhikhubhai Patel,
  10% owner